When the Drugs Don´t Work
summary
A blood‑based test uses a host immune signature—measuring proteins (started from 600 candidates) and reduced to a three‑marker panel (TRAIL, IP‑10, CRP) to classify bacterial vs viral infection. A 1,002‑patient prospective study yields roughly 94% sensitivity and 93% specificity. A benchtop CE‑IVD product runs in about two hours, is already used in >5,000 children, and the company is running 10 studies with >10,000 patients while developing a one‑drop, minutes‑to‑result second generation (~18 months away).
AI-written summary · about